around.pk
Thursday, 19 November 2026
☀ Karachi 28°☀ Lahore 20°⛅ Islamabad 15°
Health

Experimental Blood Cancer Vaccine Cuts Death Risk by 41% in Phase 3 Trial

A therapeutic vaccine for acute myeloid leukemia, developed at Memorial Sloan Kettering and tested by Sellas Life Sciences, extended median survival to 24 months versus 14.7 months for standard treatments.

around.pk·just now

An experimental vaccine for an aggressive form of blood cancer has delivered encouraging results in a late-stage clinical trial, cutting the risk of death among certain leukemia patients by 41 percent, according to the developer.

The therapy, known as galinpepimut-S (GPS), was originally developed at Memorial Sloan Kettering Cancer Center and was tested by US-based Sellas Life Sciences in a Phase 3 trial involving 126 patients with acute myeloid leukemia (AML). Patients who received the vaccine survived a median of 24 months, compared with 14.7 months for those given other available treatments.

AML is a fast-moving blood cancer diagnosed in roughly 20,000 people each year in the United States. Chemotherapy can push the disease into remission, but it often returns, which makes durable, long-term control difficult to achieve. The trial enrolled patients whose leukemia had come back after earlier treatment but who had entered another remission and were not eligible for bone marrow transplants.

Unlike conventional vaccines that prevent disease, GPS is designed to train the immune system to recognise and attack leftover leukemia cells following chemotherapy, with the aim of lowering the chance of relapse. It works by using peptides, which are fragments of proteins, to trigger an immune response against cancer cells, and it can be manufactured as an off-the-shelf product rather than being customised for each patient.

Sellas said the vaccine was generally well tolerated, with injection-site reactions reported as the most common side effect. The company plans to present detailed findings at a future medical conference and to seek approval from the US Food and Drug Administration, with a regulatory application expected in the first half of 2027.

The results remain preliminary until full trial data are published and reviewed, but they add to growing interest in therapeutic cancer vaccines as a way to extend survival in hard-to-treat blood cancers. For patients with limited options after relapse, a ready-made treatment that works with the immune system could offer a meaningful alternative if regulators eventually clear it for use.

The story so far Health

  1. Pakistan Launches Free Hepatitis Screening and Treatment Drive, Extends Health Cards to Journalists
  2. Sindh Authorities Order Inquiry After Newborn Death at Pano Aqil Hospital
  3. FIA Raids PIMS Surgical Waste Facility, Arrests Three in Placenta Disposal Probe
  4. Rawalpindi-Kahuta Electric Bus Route Restricted to Fauji Foundation Hospital, Residents Plan Protest
See the full timeline →
United StatesHealthMemorial Sloan Kettering Cancer CenterSellas Life SciencesUS Food and Drug Administrationacute myeloid leukemiagalinpepimut-S

Continue the story

View all →

Read more